• Metformin Hydrochloride in HO and Metabolic Research Workflo

  2026-05-25

  Metformin Hydrochloride (Metformin HCl) advances both metabolic and ossification research by targeting glucose pathways and the Nr4a1/Wnt/β-catenin signaling axis. This guide distills new protocols and troubleshooting strategies for maximizing reproducibility and insight in in vitro and in vivo applications.

• Rifampin (SKU B2021): Precision in Transcription Inhibition

  2026-05-24

  This article addresses key laboratory challenges in cell-based assays and synthetic biology by illustrating how Rifampin (SKU B2021) delivers reproducible, data-driven solutions for transcription inhibition. Integrating scenario-based analysis, it guides biomedical researchers in optimizing assay reliability, interpreting results, and selecting high-quality reagents, all grounded in evidence and best practices.

• Dual Ubiquitin Binding by SPRTN Accelerates DNA-Protein Cros

  2026-05-23

  This study uncovers how the SPRTN protease achieves rapid and selective degradation of polyubiquitinated DNA-protein crosslinks (DPCs) through a dual ubiquitin-binding mechanism. These findings reveal the molecular basis of SPRTN's substrate specificity and have implications for genome stability and translational protein analysis.

• Applied Use of BGJ398 (NVP-BGJ398) in FGFR-Driven Research

  2026-05-22

  BGJ398 (NVP-BGJ398) offers unmatched selectivity for FGFR1/2/3, enabling precise interrogation of FGFR-driven malignancies and developmental signaling. This guide delivers actionable workflows, troubleshooting insights, and protocol parameters to optimize oncology and developmental biology research with APExBIO's trusted inhibitor.

• Ziprasidone Augmentation in Anxious Depression: Study Insigh

  2026-05-22

  This article examines the pivotal findings from a randomized, double-blind trial evaluating ziprasidone augmentation of escitalopram in patients with anxious versus nonanxious depression. The study offers important insights into the nuanced antidepressant and anxiolytic responses to combined pharmacotherapy, highlighting implications and limitations for translational research.

• Demethyleneberberine in Inflammation & Cancer: Protocols & P

  2026-05-21

  Demethyleneberberine (DMB) stands out as a multi-pathway inhibitor for inflammation and cancer research, enabling reproducible, high-fidelity modeling in vitro and in vivo. This article delivers actionable workflows, advanced troubleshooting, and translational insight to maximize DMB’s impact in ulcerative colitis and NSCLC assays.

• Necrostatin 2: Optimizing Necroptosis Inhibition Workflows

  2026-05-21

  Necrostatin 2 (Nec-2) delivers nanomolar precision for dissecting necroptosis in models where apoptosis is suppressed. This guide bridges cutting-edge membrane biology with hands-on protocol enhancements, advanced troubleshooting, and insights from recent discoveries in programmed cell death.

• Dinaciclib Exploits VHL Deficiency in Clear Cell Renal Carci

  2026-05-20

  This study demonstrates that the cyclin-dependent kinase inhibitor Dinaciclib induces synthetic lethality in VHL-deficient clear cell renal cell carcinoma (CC-RCC), selectively targeting tumor cells while sparing normal tissue. The findings underscore a promising avenue for targeted therapy in CC-RCC, supported by robust in vitro and in vivo evidence.

• Itraconazole in Candida Biofilm Research: Protocols and Inno

  2026-05-20

  Itraconazole, a triazole antifungal agent, is redefining antifungal assay workflows by leveraging its dual action as a CYP3A4 inhibitor and biofilm disruptor. Integrating recent breakthroughs in PP2A-mediated drug resistance, this guide details practical protocols, troubleshooting, and comparative insights to help researchers overcome persistent Candida challenges.

• Bufuralol Hydrochloride: Precision Tools for Human Intestina

  2026-05-19

  Explore how Bufuralol hydrochloride advances cardiovascular pharmacology research as a non-selective β-adrenergic receptor antagonist, with a novel focus on human iPSC-derived intestinal organoids for translational pharmacokinetic modeling. Gain unique insights beyond conventional protocols and troubleshooting guides.

• ER Stress and Cytokine Storm Drive Pro-Metastatic States in

  2026-05-19

  Conod et al. (2022) reveal that tumor cells surviving impending death acquire prometastatic states through ER stress, nuclear reprogramming, and a cytokine storm. This work uncovers previously uncharacterized cell populations and signaling axes that underlie metastasis initiation, offering new mechanistic targets for therapeutic intervention.

• GCG Disrupts SARS-CoV-2 Nucleocapsid Phase Separation: Mecha

  2026-05-18

  This study reveals that the SARS-CoV-2 nucleocapsid protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process essential for viral replication and assembly. The natural polyphenol GCG, derived from green tea, is shown to inhibit this phase separation and suppress viral replication, providing a mechanistically grounded target for antiviral intervention.

• Coronavirus Macrodomains, PARP Inhibition, and Innate Immuni

  2026-05-18

  Grunewald et al. (2019) demonstrate that the coronavirus macrodomain counters poly(ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and enhancement of interferon (IFN) production. This study identifies PARP12 and PARP14 as key antiviral effectors, highlighting the macrodomain’s essential role in immune evasion and suggesting new research avenues for host-virus interactions.

• Intestinal TM6SF2 Maintains Gut–Liver Axis to Prevent MASH

  2026-05-17

  This study demonstrates that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) by maintaining gut barrier integrity and regulating host–microbiota interactions. The findings reveal a mechanistic link between intestinal lipid handling, lysophosphatidic acid (LPA) signaling, and liver inflammation, suggesting new avenues for therapeutic intervention.

• Partial BACE1 Inhibition Reduces Amyloid-β Without Synaptic

  2026-05-16

  Satir et al. (2020) provide evidence that partial inhibition of BACE1, leading to up to 50% reduction in amyloid-β (Aβ) production, does not impair synaptic transmission in primary cortical neurons. These findings inform dosing paradigms for BACE1 inhibitors in Alzheimer's disease research, supporting moderate target engagement to avoid functional side effects.

466 records 18/32 page Previous Next First page 上5页 1617181920 下5页 Last page